- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BlossomHill auf der Guggenheim-Konferenz: Makrozyklische Wirkstoffe als neue Kraft in der Onkologie | - | Investing.com Deutsch | ||
| 04.11. | BlossomHill to present BH-30236 data at ASH meeting in December | 4 | Investing.com | ||
| 22.10. | BlossomHill partners with Foundation Medicine on diagnostic test | 1 | Investing.com | ||
| 22.10. | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer | 1 | GlobeNewswire (USA) | ||
| 30.09. | H.C. Wainwright bestätigt Kaufempfehlung für BlossomHill mit Kursziel von 35 US-Dollar | 2 | Investing.com Deutsch | ||
| BLOSSOMHILL THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.09. | H.C. Wainwright reiterates Buy on BlossomHill stock, $35 target | 1 | Investing.com | ||
| 28.09. | BlossomHill: Vielversprechende präklinische Daten zu pan-KRAS-Inhibitor BH-501284 | 2 | Investing.com Deutsch | ||
| 21.09. | Guggenheim raises BlossomHill Therapeutics price target to $40 on pipeline progress | 1 | Investing.com | ||
| 18.09. | BlossomHill Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 18.09. | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results | 355 | GlobeNewswire (Europe) | Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive... ► Artikel lesen | |
| 17.09. | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | 1.575 | AFX News | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| 16.09. | BlossomHill closes up 18% on strongest day since August IPO | 2 | Seeking Alpha | ||
| 15.09. | BlossomHill Therapeutics bei H.C. Wainwright: Daten zum Hauptwirkstoff verbessern den Ausblick | 4 | Investing.com Deutsch | ||
| 15.09. | Starke Studiendaten und Investorenkonferenz treiben Aktie von BlossomHill Therapeutics an | 1 | Investing.com Deutsch | ||
| 15.09. | BlossomHill Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.09. | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World ... | 1 | GlobeNewswire (USA) | ||
| 01.09. | JPMorgan nimmt Coverage von BlossomHill Therapeutics mit "Overweight" auf | 2 | Investing.com Deutsch | ||
| 01.09. | JPMorgan initiates BlossomHill Therapeutics stock with overweight | 1 | Investing.com | ||
| 31.08. | Biotech Stocks At 52-Week Highs - RenovoRx +12%, BlossomHill Therapeutics, Revvity, AtriCure, Biofrontera Inc. | 837 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.RenovoRx... ► Artikel lesen | |
| 18.08. | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC | 741 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
Das Unternehmen BLOSSOMHILL THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 14,220 Euro und damit -0,14 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BLOSSOMHILL THERAPEUTICS INC finden Sie auf Wallstreet Online.